$4.35 Million in Sales Expected for OptiNose Inc (OPTN) This Quarter

Equities analysts predict that OptiNose Inc (NASDAQ:OPTN) will announce sales of $4.35 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for OptiNose’s earnings, with estimates ranging from $4.30 million to $4.39 million. OptiNose reported sales of $870,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 400%. The business is expected to report its next earnings results on Monday, May 13th.

According to Zacks, analysts expect that OptiNose will report full year sales of $36.51 million for the current fiscal year, with estimates ranging from $35.30 million to $37.73 million. For the next fiscal year, analysts expect that the firm will report sales of $84.42 million, with estimates ranging from $78.50 million to $90.35 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow OptiNose.

OptiNose (NASDAQ:OPTN) last released its quarterly earnings data on Wednesday, March 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.20. OptiNose had a negative net margin of 1,509.87% and a negative return on equity of 77.32%. The company had revenue of $3.02 million for the quarter, compared to analysts’ expectations of $2.60 million.

Several research analysts have issued reports on OPTN shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $27.00 price target on shares of OptiNose in a report on Monday, February 4th. Zacks Investment Research upgraded OptiNose from a “sell” rating to a “hold” rating in a report on Tuesday, January 15th. ValuEngine lowered OptiNose from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, Royal Bank of Canada cut their target price on OptiNose to $25.00 and set an “outperform” rating on the stock in a report on Thursday, March 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. OptiNose presently has a consensus rating of “Buy” and an average price target of $28.00.

Several institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of OptiNose in the fourth quarter valued at approximately $45,000. Teachers Advisors LLC lifted its stake in OptiNose by 31.9% during the 3rd quarter. Teachers Advisors LLC now owns 31,601 shares of the company’s stock valued at $393,000 after acquiring an additional 7,641 shares in the last quarter. Rhumbline Advisers boosted its holdings in OptiNose by 58.5% during the 4th quarter. Rhumbline Advisers now owns 23,709 shares of the company’s stock worth $147,000 after acquiring an additional 8,748 shares during the last quarter. Stifel Financial Corp purchased a new position in OptiNose during the 4th quarter worth $63,000. Finally, Vanguard Group Inc. boosted its holdings in OptiNose by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 779,689 shares of the company’s stock worth $9,691,000 after acquiring an additional 12,404 shares during the last quarter. 56.90% of the stock is owned by hedge funds and other institutional investors.

OPTN stock traded down $0.23 during trading on Monday, reaching $9.95. 150,395 shares of the stock were exchanged, compared to its average volume of 152,703. OptiNose has a twelve month low of $5.66 and a twelve month high of $30.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 8.01 and a current ratio of 8.28. The company has a market cap of $420.07 million, a P/E ratio of -3.71 and a beta of 0.79.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Further Reading: Diversification

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.